1. Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the run-in period

2. Patients who have had a respiratory tract infection within 6 weeks prior to Visit 1

3. Patients with concomitant pulmonary disease

4. Patients with a history of asthma

5. Patients with diabetes Type I or uncontrolled diabetes Type II

6. Any patient with lung cancer or a history of lung cancer

7. Patients with a history of certain cardiovascular comorbid conditions

8. Patients who have been exposed to indacaterol previously. (Except for any patient who enrolled in Study CQAB149B1302)

Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)